CLDX earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -8.14. Updated 2026-07-23.
Celldex Therapeutics (CLDX) Research Hub
Celldex Therapeutics (CLDX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 36.9 USD (-4.85%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.14, market cap 2.26B. This hub links to the full technical, earnings and options research available for CLDX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 36.9 USD (-4.85%) |
| 52-week range | 31.05 USD – 45.13 USD |
| Trend regime | Range |
| 14-day RSI | 31.3 (Bearish) |
| Trailing P/E | -8.14 |
| Market cap | 2.26B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for CLDX
Covered Call on CLDX: how it works, illustrative setup around the real 36.9 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CLDX: how it works, illustrative setup around the real 36.9 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CLDX: how it works, illustrative setup around the real 36.9 USD price, max profit/loss, breakeven and when to use it. Educational.
CLDX technical analysis: range, last 36.9 USD, RSI 31.3, 52w range 31.05 USD–45.13 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CLDX in?
Celldex Therapeutics (CLDX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CLDX in an uptrend or downtrend?
As of 2026-09-11, CLDX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CLDX's trailing P/E ratio?
CLDX's trailing P/E is -8.14, with a market cap of 2.26B. See the earnings research page for full valuation detail.
When does CLDX next report earnings?
CLDX is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -1.04 USD.